Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

Melanoma/Skin Cancers
Session Type and Session Title: 
Poster Highlights Session, Melanoma/Skin Cancers
Abstract Number: 
J Clin Oncol 32:5s, 2014 (suppl; abstr 9029^)
Igor Puzanov, Mohammed M. Milhem, Robert Hans Ingemar Andtbacka, David R. Minor, Omid Hamid, Ai Li, Michael Chastain, Kevin Gorski, Abraham Anderson, Ari M. Vanderwalde, Jeffrey Chou, Howard Kaufman; Vanderbilt-Ingram Cancer Center, Vanderbilt University, School of Medicine, Nashville, TN; University of Iowa Hospitals and Clinics, Iowa City, IA; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; California Pacific Melanoma Center, San Francisco, CA; The Angeles Clinic and Research Institute, Los Angeles, CA; Department of Biostatistics and Epidemiology, Amgen Inc., Thousand Oaks, CA; Amgen Inc., Seattle, WA; Amgen Inc., Thousand Oaks, CA; Amgen, Inc., Thousand Oaks, CA; Rush University Medical Center, Chicago, IL

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

Abstract Disclosures


Background: T-VEC, an HSV-1 derived oncolytic immunotherapy designed to induce systemic antitumor immunity, showed a ≥ 6 mos higher durable response rate vs GM-CSF in a phase 3 melanoma trial (Andtbacka et al. ASCO 2013). This phase 1b/2 study will determine the safety and efficacy of T-VEC as a priming regimen when added to ipi. Methods: Phase 1b studied the safety of T-VEC+ipi. Objective response rate (ORR) was also evaluated with tumor assessments q12w. Blood was collected pre- and post-treatment (tx) for correlative studies. Key criteria: unresected Stage IIIB-IV melanoma, no prior systemic tx, measurable disease, and ≥1 injectable cutaneous, subcutaneous or nodal lesion. T-VEC was given intralesionally at ≤ 4 mL of 106 PFU/mL at wk 1, then 108 PFU/mL at wk 4 and then q2w. Ipi 3 mg/kg q3w was given as 4 infusions starting wk 6. Tx continued until DLT, intolerance, all injectable tumors disappeared, or disease progression (PD) per Immune Related Response Criteria. DLT was any grade (gr) ≥ 4 adverse event (AE) or gr ≥ 3 immune-related AE within the first 6 wks of ipi tx. Results: Of 19 patients (pts) enrolled: 42% men, 42% ≥ 65 yrs, 58% Stage IV M1b/c; 18 pts received T-VEC+ipi. No DLTs were reported. Gr 3/4 AEs occurred in 32%. 2 pts had possible immune-related gr 3/4 AEs: 1 pt had gr 3 hypophysitis (attributed to ipi) and gr 3 adrenal insufficiency and gr 3 diarrhea (both attributed to combination), and 1 pt had gr 4 amylase+lipase attributed to ipi. PD (CNS metastases) led to one gr 5 AE. By 15 Oct 13 (data cutoff), median tx duration of T-VEC was 13.3 wks. Of 17 pts with investigator assessed response, ORR was 41% (24% CR, 18% PR); 35% had SD. Median time to response was 2.9 mos. By flow cytometry, activated CD8 T cells significantly increased from baseline 1.8x after T-VEC alone and 2.9x during T-VEC+ipi tx. Conclusions: T-VEC+ipi appears to be tolerable with no DLTs. In consideration with published reports, these data, although preliminary, suggest higher CR and OR rates than either agent alone and earlier responses after ipi initiation during T-VEC+ipi than with ipi alone. Additional immunophenotyping and phase 2 (ipi vs T-VEC+ipi) are ongoing. Clinical trial information: NCT01740297.